EE200100382A - Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod - Google Patents

Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod

Info

Publication number
EE200100382A
EE200100382A EEP200100382A EEP200100382A EE200100382A EE 200100382 A EE200100382 A EE 200100382A EE P200100382 A EEP200100382 A EE P200100382A EE P200100382 A EEP200100382 A EE P200100382A EE 200100382 A EE200100382 A EE 200100382A
Authority
EE
Estonia
Prior art keywords
cyclodextrin
ras
hydroxypropyl
complex
preparation
Prior art date
Application number
EEP200100382A
Other languages
English (en)
Estonian (et)
Inventor
S. Raghavan Krishnaswamy
M. Malloy Timothy
A. Varia Sailesh
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE200100382A publication Critical patent/EE200100382A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100382A 1999-01-21 1999-12-21 Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod EE200100382A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11664799P 1999-01-21 1999-01-21
PCT/US1999/030424 WO2000042849A1 (en) 1999-01-21 1999-12-21 COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD

Publications (1)

Publication Number Publication Date
EE200100382A true EE200100382A (et) 2002-12-16

Family

ID=22368422

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100382A EE200100382A (et) 1999-01-21 1999-12-21 Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod

Country Status (33)

Country Link
US (1) US6218375B1 (lv)
EP (1) EP1143796A4 (lv)
JP (1) JP2002535253A (lv)
KR (1) KR100708360B1 (lv)
CN (1) CN1219517C (lv)
AR (1) AR022323A1 (lv)
AU (1) AU772204B2 (lv)
BG (1) BG105666A (lv)
BR (1) BR9916566A (lv)
CA (1) CA2359646C (lv)
CO (1) CO5160253A1 (lv)
CZ (1) CZ20012601A3 (lv)
EE (1) EE200100382A (lv)
GE (1) GEP20043214B (lv)
HK (1) HK1038865A1 (lv)
HU (1) HUP0105160A3 (lv)
ID (1) ID30139A (lv)
IL (1) IL144025A (lv)
LT (1) LT4893B (lv)
LV (1) LV12712B (lv)
MY (1) MY119700A (lv)
NO (1) NO20013585L (lv)
NZ (1) NZ511995A (lv)
PE (1) PE20001419A1 (lv)
PL (1) PL195280B1 (lv)
RU (1) RU2230062C2 (lv)
SK (1) SK9602001A3 (lv)
TR (1) TR200102109T2 (lv)
TW (1) TWI232752B (lv)
UA (1) UA67825C2 (lv)
UY (2) UY25986A1 (lv)
WO (1) WO2000042849A1 (lv)
ZA (1) ZA200104416B (lv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
EP1443936A4 (en) * 2001-11-13 2006-01-11 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUE-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040009972A1 (en) * 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
AU2006299501B2 (en) * 2005-09-30 2012-11-29 Lundbeck Llc Novel parenteral carbamazepine formulation
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
MX2009005368A (es) * 2006-11-21 2009-06-05 Novartis Ag Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
RU2627460C2 (ru) * 2010-05-26 2017-08-08 Нейрофиксиа Б.В. Составы 2-иминобиотина и их применение
WO2012034038A2 (en) * 2010-09-09 2012-03-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
ES2642843T3 (es) * 2011-10-07 2017-11-20 Pisces Therapeutics Llc Tratamiento de enfermedad maligna y no maligna con antagonistas de Ras
CN105194685A (zh) * 2015-10-15 2015-12-30 重庆大学 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂
PL3389653T3 (pl) 2015-12-16 2024-02-26 Neurophyxia B.V. 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
CA3240887A1 (en) * 2021-12-15 2023-06-22 Luc BURY Pharmaceutical compositions comprising modified beta-cyclodextrins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1067639A (ja) * 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンe−ビタミンcリン酸ジエステル/シクロデキストリン包接物及び該包接物を配合した皮膚外用剤

Also Published As

Publication number Publication date
ID30139A (id) 2001-11-08
US6218375B1 (en) 2001-04-17
AR022323A1 (es) 2002-09-04
LV12712B (lv) 2002-01-20
TWI232752B (en) 2005-05-21
PE20001419A1 (es) 2001-02-21
RU2230062C2 (ru) 2004-06-10
LT2001064A (en) 2001-10-25
CA2359646A1 (en) 2000-07-27
CO5160253A1 (es) 2002-05-30
EP1143796A1 (en) 2001-10-17
NO20013585D0 (no) 2001-07-20
ZA200104416B (en) 2002-05-29
AU2374000A (en) 2000-08-07
IL144025A (en) 2004-05-12
CN1333651A (zh) 2002-01-30
NZ511995A (en) 2003-11-28
BG105666A (en) 2002-04-30
GEP20043214B (en) 2004-04-26
MY119700A (en) 2005-06-30
NO20013585L (no) 2001-09-04
HK1038865A1 (zh) 2002-04-04
UY25986A1 (es) 2000-09-29
IL144025A0 (en) 2002-04-21
PL195280B1 (pl) 2007-08-31
HUP0105160A2 (hu) 2002-05-29
KR20010101611A (ko) 2001-11-14
SK9602001A3 (en) 2002-06-04
PL366338A1 (en) 2005-01-24
JP2002535253A (ja) 2002-10-22
UY25987A1 (es) 2000-09-29
CA2359646C (en) 2008-12-02
CZ20012601A3 (cs) 2002-05-15
HUP0105160A3 (en) 2003-01-28
WO2000042849A1 (en) 2000-07-27
AU772204B2 (en) 2004-04-22
UA67825C2 (uk) 2004-07-15
LV12712A (lv) 2001-09-20
EP1143796A4 (en) 2002-03-20
LT4893B (lt) 2002-02-25
TR200102109T2 (tr) 2001-12-21
KR100708360B1 (ko) 2007-04-17
CN1219517C (zh) 2005-09-21
BR9916566A (pt) 2001-11-13

Similar Documents

Publication Publication Date Title
EE200100382A (et) Ras-farnesüültransferaasi inhibiitori ja sulfobutüüleeter-7-ß-tsüklodekstriini või 2-hüdroksüpropüül-ß-tsüklodekstriini kompleks ja selle valmistamise meetod
FI980970A (fi) Menetelmä ja laitteisto sähköpostin käsittelemiseksi
DE60024972D1 (de) Wiederbeschreibbare cd und deren herstellungsverfahren
ID26848A (id) Koupling untuk gigi-gigi eksapator dan sejenisnya
AU2001284695A1 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
NO20021587D0 (no) Sementeringsblandinger og bruk av slike blandinger for sementering av brönner eller lignende
NO20015004L (no) Vandig desinfiseringsmiddel og sammensetning for vask av harde overflater samt fremgangsmåte for anvendelse derav
DE60123694D1 (de) Integriertes Hydroisomerizierungs- und Alkylierungsverfahren
NO20005017D0 (no) Metoder og viskøse sammensetninger for behandling av brønner
ID28752A (id) Metode-metode dan komposisi-komposisi sanitasi
FI20000032A0 (fi) Järjestely ja menetelmä pinnan tarkistamiseksi
FI20000126A (fi) Menetelmä ja mittalaite mitata suspensiota
FI20000292A0 (fi) Testausjärjestely ja testausmenetelmä
NO20005763L (no) DHEA-sammensetning og fremgangsmåte
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
EE200100305A (et) Preparaat, selle kasutamine ja valmistamismeetod
FI980269A (fi) Menetelmä norborneenin ja sen johdannaisten syntetisoimiseksi
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
EE200200674A (et) Biosensor ja selle valmistamise meetod
FI20011448A0 (fi) Menetelmä ja järjestely liittimen kunnon ja kytkentöjen eheyden määrittämiseksi
FI990632A (fi) Päisteputken asennusmenetelmä ja siinä käytettävä vetolaite
NO982501D0 (no) FremgangsmÕte for fryset°rking av l°sninger
UA34207A (uk) Спосіб резекції щитоподібної залози при багатовузловому зобі
FI990744A (fi) Lyhytviipymäpäällystin ja lyhytviipymäpällystysmenetelmä
IDP000012859A (id) Zat penguat kertas dan metoda untuk memperkuat kertas